



## EDITOR'S PAGE

# The evolution in the management of aortic valve disease: From surgical techniques to transcatheter interventions



Valvular heart disease represent a mechanical failure of valve apparatus and when severe, strategies to restore mechanical function by surgical repair or replacement or by invasive strategies are consider the gold standard of treatment.

Aortic stenosis is mainly a degenerative deteriorating and morbid disease, when left untreated, which was used to manage by surgical replacement of the aortic valve (SAVR).<sup>1</sup> Over the last 10–15 years transcatheter aortic valve replacement (TAVR) revolutionized the management of patients with aortic stenosis. The Placement of Aortic Transcatheter Valves (PARTNER) trial and the CoreValve US Pivotal trial have shown that bioprosthetic valves can be effectively transcatheterely implanted in severely stenotic and calcified natural or bioprosthetic aortic valves and to increase survival in patients unsuitable for operation.<sup>2,3</sup> Improving equipment and expanding experience<sup>4,5</sup> have broaden the indications including healthier patients with intermediate surgical risk while a few registries and randomized control trials have even applied this revolutionized technology even in patients with low risk ([Table 1](#)).

However, we should notice that although data are in favor of TAVR in selected intermediate risk patients there are no convincing data in low risk populations since despite the positive results from randomized control data, date from registries representing every day clinical life are not unequivocal. Nevertheless, evolution of TAVR cannot stop and in depth involvement of anesthesiologists in the peri-procedural management and type of anesthesia may improve short term outcome and eliminate complications in the future which may turn the balance in favor of TAVR even in intermediate and low risk patients as is discussed by Melidi et al. in this issue of Hellenic Journal of Cardiology.<sup>11</sup> However, complicated cases with annular Aortic annular

erosion and abscess will continue to manage surgical with either aortic valve translocation or left ventricle outflow tract reconstruction which seems to have similar post-operative outcomes as Perrotta et al. conclude after review of the literature.<sup>12</sup> Surgical management is also the only effective treatment in complicated cases such as those presented in this issue of Hellenic journal of cardiology with sequential spontaneous severe aortic and mitral regurgitation<sup>13</sup> and with interrupted aortic arch with post interruption aneurysm and bicuspid aortic valve.<sup>14</sup>

In this issue of Hellenic journal of cardiology interesting data on coronary artery disease and atherosclerosis are also discussed. Endothelial shear stress is considered as the most prominent factor driving the diversity in atherosclerosis progression. However as discuss by Zaromytidou et al.<sup>15</sup> at the moment techniques to access endothelial shear stress such as intravascular ultrasonography or optical coherence tomography are invasive. Nevertheless, noninvasive modalities are under development which may change the management of coronary artery disease focusing on high risk lesions. From another approach Katsimpoulas et al. examined the combined effects of exercise training and endocannabinoid receptor 1 inhibitor (Rimonabant) on atherosclerosis burden and composition of apolipoprotein E-deficient mice concluding that such an approach can reduced plaque macrophages and matrix metalloproteinases inducing plaque regression and promoting plaque stability.<sup>16</sup> Epidemiological data from the MEDIS study in inhabitants of the Eastern Aegean islands with a relative low incidence of cardiovascular disease show that overall cardiovascular disease risk seems to be low among Eastern Aegean Islanders highlighting the role of primary and secondary prevention in the management of coronary artery disease.<sup>17</sup>

Finally, interesting data on an upcoming modality of cardiovascular imaging, cardiac magnetic resonance, are discuss and presented emphasizing the role of novel

Peer review under responsibility of Hellenic Society of Cardiology.

**Table 1** Representatives studies on the outcome of transcatheter aortic valve replacement in subjects of variable operative risk.

Study	Study type design	Patient population	Patient characteristic/risk	Main findings
PARTNER trial 2011 <sup>6</sup>	Randomized control	699	Patients at high surgical risk	Similar rates of survival at 1 year with transcatheter and surgical procedures
U.S. CoreValve High Risk Study 2014 <sup>7</sup>	Randomized control	795	Patients at high surgical risk	Significantly higher rate of survival at 1 year with transcatheter compared to surgical replacement
Thourani et al. 2016 <sup>8</sup>	Observational/propensity score	1710	Patients at intermediate risk	Significant superiority for death from any cause, all strokes, and incidence of moderate or severe aortic regurgitation for TAVR compared to SAVR
The Nordic Aortic Valve Intervention Trial (NOTION) 2015 <sup>9</sup>	Randomized Prospective cohort	280 patients	82% of the patients population was of low surgical risk	No significant difference between TAVR and SAVR was found for the composite rate of death from any cause, stroke, or MI after 1 year
The Observational Registry of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OBSERVANT) registry <sup>10</sup>	Registry	710	Patients at low risk	significantly better 3-year survival and freedom from major adverse cardiac and cerebrovascular events were observed after SAVR compared with TAVR

SAVR: Surgical replacement of the aortic valve; TAVR: transcatheter aortic valve replacement.

developments in the evaluation of complex cases of myocarditis<sup>18</sup> and mitral regurgitation<sup>19</sup> indicating the future direction of cardiovascular medicine.

## References

- Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg.* 2012;42:S1–S44.
- Leon MB, Smith CR, Mack MJ, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med.* 2010;363:1597–1607.
- Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthetic in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol.* 2014;63:1972–1981.
- Vavuranakis M, Vrachatis DA, Siasos G, et al. First in Greece Transcatheter Aortic Valve Implantation using the CoreValve Evolut-R Retrievable and Repositionable Bioprosthetic with the InLine Sheath and the EnVeo Loading Guiding Catheter: A Major Advantage for SmallDiameter Access Vessels. *Hellenic J Cardiol.* 2015;56:338–343.
- Spargias K, Bouboulis N, Halapas A, et al. Transaortic aortic valve replacement using the Edwards Sapien-XT Valve and the Medtronic CoreValve: initial experience. *Hellenic J Cardiol.* 2014;55:288–293.
- Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med.* 2011;364:2187–2198.
- Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med.* 2014;370:1790–1798.
- Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. *Lancet.* 2016;387:2218–2225.
- Thyregod HG, Steinbruchel DA, Ihlemann N, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. *J Am Coll Cardiol.* 2015;65:2184–2194.
- Rosato S, Santini F, Barbanti M, et al. Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Low-Risk Patients. *Circ Cardiovasc Interv.* 2016;9:e003326.
- Melidi E, Latsios G, Toutouzas K, et al. Cardio-Anesthesiology considerations for the Trans-Catheter Aortic Valve Implantation (TAVI) procedure. *Hellenic J Cardiol.* 2016;57:401–406. <http://dx.doi.org/10.1016/j.hjc.2016.10.001>.
- Perrotta S, Lentini S. Surgical management of severely damaged aortic annulus. *Hellenic J Cardiol.* 2016;57:382–388. <http://dx.doi.org/10.1016/j.hjc.2016.11.012>.
- Roubelakis A, Streutker C, Butany J, Bonneau D. Sequential spontaneous severe aortic and mitral regurgitation. *Hellenic J Cardiol.* 2016;57:438–440. <http://dx.doi.org/10.1016/j.hjc.2016.11.010>.
- Patel DM, Maldjian PD, Lovoulos C. Interrupted Aortic Arch with Post Interruption Aneurysm and Bicuspid Aortic Valve in an Adult: A Case Report and Literature Review. *Radiol Case Rep.* 2015 Jul 14;10(3):5–8.
- Zaromytidou M, Siasos G, Coskunb AU, et al. Intravascular hemodynamics and coronary artery disease: new insights and clinical implications. *Hellenic J Cardiol.* 2016;57:389–400. <http://dx.doi.org/10.1016/j.hjc.2016.11.019>.
- Katsimpoulas M, Kadoglou NE, Moustardas P, et al. The role of exercise training and endocannabinoid system in atherosclerotic plaque burden and composition in Apo-E deficient mice.

- Hellenic J Cardiol.* 2016;57:417–425. <http://dx.doi.org/10.1016/j.hjc.2016.11.013>.
17. Foscolou A, Polychronopoulos E, Paka E, et al. Lifestyle and Health Determinants of Cardiovascular Disease among Greek older adults living in Eastern Aegean Islands: an adventure within the MEDIS study. *Hellenic J Cardiol.* 2016;57:407–414. <http://dx.doi.org/10.1016/j.hjc.2016.11.021>.
18. Chrysanthou C, Antoniou CK, Stillman A, Lalude O, Henry T, Lerakis S. Myocardial fibrosis detected with Gadolinium Delayed Enhancement in Cardiac Magnetic Resonance Imaging and Ventriculoarterial Coupling alterations in patients with Acute Myocarditis. *Hellenic J Cardiol.* 2016;57:449–454.
19. Aggeli C, Felekos I, Tousoulis D. MRI in all MR Patients: Is this the "Gold Standard" Approach? *Hellenic J Cardiol.* 2016;57:455–456.

Dimitris Tousoulis, MD, PhD \*  
1st Cardiology Department, National and Kapodistrian University of Athens University Medical School, Hippokration Hospital, Athens, Greece

\*Prof. Dimitris Tousoulis, MD, PhD, FESC, FACC, Vasilissis Sofias 114, TK 115 28, Hippokration Hospital, Athens, Greece. Tel.: +30 213 2088099; fax: +30 213 2088676.  
E-mail address: [drtousoulis@hotmail.com](mailto:drtousoulis@hotmail.com)

24 November 2016  
Available online 18 April 2017